Loading…
Maker of contact lenses (CooperVision) and women's health/fertility medical devices (CooperSurgical).
Maker of contact lenses (CooperVision) and women's health/fertility medical devices (CooperSurgical).
Contact lenses are sold through eye-care professionals and large retailers, and many wearers re-buy daily or monthly lenses, which keeps revenue recurring. CooperSurgical sells fertility lab products, women's health devices and genetic testing to clinics and hospitals. MiSight, a lens for slowing myopia in children, is a growth item.
Moat: narrow (brand, installed base, switching costs). Established contact-lens brand portfolio (myopia management) plus a leading fertility/IVF device franchise.
Headquarters: San Ramon, California, USA · Founded: 1958 · Employees: 15,000
Size Cooper Companies (The) (COO) is a United States Health Care company (Medical Specialties) with a market value of $11.9B, the 700th largest of 3,117 United States companies the cockpit tracks. Shares closed at $62.36 on 6 Nov 2026.
Performance Over six months the shares gained 3.9%, against +33.8% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +4.9%); the operating margin is 19.3% (peer median 14.2%).
Valuation It trades at 13.8× forward earnings against a peer median of 20.4× (2nd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.4 points below its cost of capital (8.4% WACC).
Short interest Short interest is 4.8% of the free float (15 Oct 2026).
Next results Next results expected around 3 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $4.24B | $4.09B | $3.90B | $3.59B | $3.31B |
| Revenue growth | — | +5% | +8% | +9% | — |
| Gross profit | $2.60B | $2.48B | $2.39B | $2.17B | $1.99B |
| EBITDA | $1.20B | $1.11B | $1.12B | $909M | $929M |
| Net income | $570M | $375M | $392M | $294M | $386M |
| Free cash flow | $678M | $434M | $288M | $215M | $450M |
| Capital expenditure | $355M | $362M | $421M | $392M | $242M |
| Total debt | $2.54B | $2.78B | $2.85B | $2.82B | $3.00B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cooper Companies (The) COO | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% |
| Alcon ALC.SW | $37.5B | +22% | -1% | 11% | 21.4× | 12.9% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| Bausch + Lomb BLCO.TO | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% |
| Menicon 7780.T | $854M | +12% | +5% | 9% | 19.3× | n/a |
| Vitrolife VITR.ST | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.8% | +8.4% | 7th highest of 21 |
| 6-month return | +3.9% | +33.8% | 5th lowest of 21 |
| Distance from 52-week high | -30.6% | -12.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | +4.7% | +4.9% | 11th highest of 21 |
| Operating margin | 19.3% | 14.2% | 5th highest of 21 |
| Forward P/E | 13.8× | 20.4× | 2nd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 9.4% | 10.7% | 9th least demanding of 19 |
| Growth delivered (Del g) | +11.0% | +7.8% | 6th highest of 19 |
| Hurdle (Req g minus delivered) | -1.6 pp | +4.4 pp | 7th least demanding of 19 |
| ROIC minus cost of capital | -2.4 pp | +2.5 pp | 8th lowest of 21 |
| EV / EBITDA | 11.9× | 14.2× | 9th cheapest of 18 |
| Net debt / EBITDA | 2.0× | 0.7× | 6th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cooper Companies (The) COO | United States | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% | +10.3% |
| Olympus 7733.T | Japan | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% | +6.7% |
| Demant A/S DEMANT.CO | Denmark | $11.6B | +62% | +10% | 18% | 25.7× | 6.8% | +9.8% |
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% | +5.5% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Avantor AVTR | United States | $10.5B | +86% | +1% | 8% | 17.7× | 16.1% | +0.5% |
| Qiagen QGEN | United States | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% | +2.2% |
| Bio-Rad Laboratories BIO | United States | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% | +0.3% |
| Insulet PODD | United States | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% | +24.5% |
| Globus Medical GMED | United States | $9.54B | -9% | +20% | 22% | 14.1× | 5.5% | +30.1% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 46.9× | n/a | n/a |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
| Revvity RVTY | United States | $17.3B | +54% | +5% | 15% | 26.7× | 27.3% | -5.5% |
| Coloplast A/S COLO-B.CO | Denmark | $17.7B | +26% | +4% | 25% | 19.9× | -1.8% | +8.3% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |